FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation

FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news